CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering

Oncotarget

Volumn 7, Issue 6, 2016, Pages 7343-7353

  Singh, Rajesh ^a   Kapur, Neeraj ^a   Mir, Hina ^a   Singh, Nalinaksha ^a   Lillard, James W ^a   Singh, Shailesh ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

CXCL16; CXCR6; Ezrin; Prostate cancer; v 3 integrin

Indexed keywords

CHEMOKINE RECEPTOR CXCR6; COLLAGENASE 3; CXCL16 CHEMOKINE; EZRIN; F ACTIN; FOCAL ADHESION KINASE; GELATINASE B; INTERSTITIAL COLLAGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; VITRONECTIN RECEPTOR; ALPHA CHEMOKINE; CHEMOKINE RECEPTOR; CXCL16 PROTEIN, HUMAN; CXCR6 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; MESSENGER RNA; SCAVENGER RECEPTOR; VIRUS RECEPTOR;

ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; CYTOSKELETON; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; IMAGE PROCESSING; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINES, CXC; CYTOSKELETAL PROTEINS; CYTOSKELETON; FLOW CYTOMETRY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; MALE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CHEMOKINE; RECEPTORS, SCAVENGER; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84980639641     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6944     Document Type: Article

References (38)

1. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002; 62:1832-1837.
2. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006; 66:1311-1318.
3. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N and Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 2001; 3:33-42.
4. Singh S, Singh UP, Grizzle WE and Lillard JW, Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004; 84:1666-1676.
5. Singh S, Singh UP, Stiles JK, Grizzle WE and Lillard JW, Jr. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004; 10:8743-8750.
6. Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS and Zhang J. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res. 2008; 6:546-554.
7. Wang J, Lu Y, Wang J, Koch AE, Zhang J and Taichman RS. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res. 2008; 68:10367-10376.
8. Hu W, Liu Y, Zhou W, Si L and Ren L. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro. PLoS One. 2014; 9:e99056.
9. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM and Khanna C. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis. 2007; 24:69-78.
10. Bompard G, Sharp SJ, Freiss G and Machesky LM. Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci. 2005; 118:5393-5403.
11. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10:182-186.
12. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A and Flores-Morales A. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem. 2006; 281:29938-29948.
13. Valdman A, Fang X, Pang ST, Nilsson B, Ekman P and Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol. 2005; 48:852-857.
14. Legate KR and Fassler R. Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails. J Cell Sci. 2009; 122:187-198.
15. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R and Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol. 2007; 9:858-867.
16. Lee JT, Lee SD, Lee JZ, Chung MK and Ha HK. Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer. Oncology letters. 2013; 5:229-235.
17. Curran S and Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. European journal of cancer (Oxford, England : 1990). 2000; 36:1621-1630.
18. Harrison GM, Davies G, Martin TA, Jiang WG and Mason MD. Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction. Int J Oncol. 2002; 21:935-940.
19. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S and Lillard JW, Jr. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010; 9:85.
20. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE and Lillard JW, Jr. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010; 8:62.
21. Mir H, Singh R, Kloecker GH, Lillard JW, Jr. and Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015; 6:9985-9998. doi: 10.18632/oncotarget.3194.
22. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE and Lillard JW, Jr. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009; 125:2288-2295.
23. Gooden MJ, Wiersma VR, Boerma A, Leffers N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AM, Daemen T, Nijman HW and Bremer E. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. Br J Cancer. 2014; 110:1535-1544.
24. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, Takano Y, Yoshie O, Tsukada K and Saiki I. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007; 67:4725-4731.
25. Srivastava J, Elliott BE, Louvard D and Arpin M. Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell. 2005; 16:1481-1490.
26. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L and Ekman P. Expression of ezrin in prostatic intraepithelial neoplasia. Urology. 2004; 63:609-612.
27. Bartholow TL, Becich MJ, Chandran UR and Parwani AV. Immunohistochemical analysis of ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic adenocarcinoma. BMC Urol. 2011; 11:12.
28. Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, Arpin M, Gschmeissner S, Verveer PJ, Bastiaens PIH and Parker PJ. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. The EMBO Journal. 2001; 20:2723-2741.
29. Chen W, Lou J Fau - Evans EA, Evans Ea Fau - Zhu C and Zhu C. Observing force-regulated conformational changes and ligand dissociation from a single integrin on cells. (1540-8140 (Electronic).
30. Goel HL, Li J, Kogan S and Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer. 2008; 15:657-664.
31. Stefanidakis M and Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood. 2006; 108:1441-1450.
32. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S and Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis. 2003; 20:413-420.
33. Zheng DQ, Woodard AS, Fornaro M, Tallini G and Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999; 59:1655-1664.
34. Engl T, Relja B, Marian D, Blumenberg C, Muller I, Beecken WD, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D and Blaheta RA. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia. 2006; 8:290-301.
35. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ and Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 2007; 67:61-73.
36. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996; 85:683-693.
37. Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC and Tang CH. Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis. 2009; 30:258-268.
38. Schmittgen TD and Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101-1108.